News stories about Exelixis (NASDAQ:EXEL) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exelixis earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.9587679708308 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Exelixis, Inc. (EXEL) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Exelixis, Inc. (NASDAQ:EXEL) – Hot Stock’s Trend Recap – Nasdaq Journal (press release) (nasdaqjournal.com)
- Stocks To Watch: Exelixis Sees Relative Strength Rating Rise To 84 (finance.yahoo.com)
- Short Interest in Exelixis, Inc. (EXEL) Drops By 11.3% (americanbankingnews.com)
Several brokerages have recently issued reports on EXEL. TheStreet upgraded shares of Exelixis from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Cowen restated an “outperform” rating on shares of Exelixis in a research note on Thursday, August 10th. Needham & Company LLC raised their price objective on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Oppenheimer restated a “hold” rating on shares of Exelixis in a research note on Monday, September 25th. Finally, BidaskClub downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $31.38.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The firm had revenue of $152.50 million for the quarter, compared to the consensus estimate of $104.91 million. During the same quarter in the previous year, the company earned ($0.04) earnings per share. The business’s revenue was up 145.2% compared to the same quarter last year. analysts predict that Exelixis will post 0.49 earnings per share for the current year.
In other Exelixis news, Director Stelios Papadopoulos sold 200,000 shares of Exelixis stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $27.68, for a total transaction of $5,536,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Patrick J. Haley sold 60,640 shares of Exelixis stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $27.21, for a total transaction of $1,650,014.40. The disclosure for this sale can be found here. Insiders have sold 970,152 shares of company stock worth $25,923,457 in the last quarter. Corporate insiders own 5.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/12/04/exelixis-exel-given-daily-media-impact-score-of-0-18.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
What are top analysts saying about Exelixis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exelixis Inc. and related companies.